Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 6.29.15

      Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015 under the symbol “CUR.” More


    • HK532-IGF-1 Alzheimer’s Disease Cell Therapy Poster At ISSCR Annual Meeting 6.26.15

      Neuralstem’s HK532-IGF-1 cells enhanced learning cognition and memory consolidation in animal data presented by University of Michigan researchers, who also reported beta-amyloid plaque reduction in the cortex and hippocampus. More


    • Jonathan Lloyd Jones Appointed CFO 5.6.15

      Former CFO and/or VP of three biotech/ pharma companies and former Senior Director, Corporate Development, for Genzyme brings expertise in corporate finance, licensing, and partnering. More


    • NSI-566 ALS Phase II Topline Results Announced 3.12.15

      Cervical intervention deemed safe, 16 million cells maximum tolerated dose established, and secondary efficacy endpoints reviewed. More


          • NSI-189/MDD Neurogenic Biomarker Data Presented 11.17.14

            Depression blood-based biomarker analysis presented at CNS Summit shows NSI-189 rapidly and persistently efficacious. More